Fosun Pharma
VC Fund
Shanghai, China
Fosun Pharma is a biopharmaceutical and healthcare industry. Fosun Pharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. Fosun Pharma's operations strategically cover several important segments of the healthcare industryvalue-chain, including: pharmaceutical manufacturing, distribution and retail.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Fosun Pharma invests in
Stages Fosun Pharma invests in
Countries Fosun Pharma invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $5.1M–$31M
- Series A
- $1.4M–$17M
Investment Focus
Industry
- Health Care 19 (43%)
- Biotechnology 17 (39%)
- Medical 11 (25%)
- Pharmaceutical 11 (25%)
- Biopharma 6 (14%)
Stage
- Series A 9 (20%)
- Funding Round 6 (14%)
- Seed 5 (11%)
- Series B 5 (11%)
- Corporate Round 4 (9%)
Country
- China 25 (57%)
- United States 7 (16%)
- Israel 2 (5%)
- Hong Kong 2 (5%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cui Zhiping
Vice President and General Manager of VC Investment Department
|
Vice President and General Manager of VC Investment Department | Total investments: 3 | Find email | |
Hongfei Jia
SVP, Joint Chief Investment Officer and General Manager of International Operations Department
|
SVP, Joint Chief Investment Officer and General Manager of International Operations Department | Total investments: 0 | Find email | |
Wai Danny
Independent Non-Executive Director
|
Independent Non-Executive Director | Total investments: 0 | Find email | |
Wu Yifang
Senior vice president and Chief operating officer
|
Senior vice president and Chief operating officer | Total investments: 2 | Find email | |
Zhou Biao
SVP, General Manager of Legal Department and General Manager of Independent Inspectors Department
|
SVP, General Manager of Legal Department and General Manager of Independent Inspectors Department | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AriBio
|
AriBio is a biotechnology firm dedicated to developing therapeutic solutions for neurodegenerative disorders. At AriBio, polypharmacology is strengthened by the capabilities of advanced AI technologies. Utilizing the ARIDD™ platform, the company explores extensive molecular databases, forecasting interactions that encompass various targets andmechanisms. By harnessing AI, AriBio strives to enhance drug efficacy and broaden potential therapeutic applications. ARIDD™ serves as a drug development platform that enhances the discovery and creation of polypharmacological medications. | $7.5M / Corporate Round / Jul 03, 2026 | |
Antekin Biotech
|
Antekin Biotech is a leading vaccine company with integrated capabilities spanning the entire vaccine value chain, from research and development to manufacturing and commercialization. The company is dedicated to advancing innovative vaccine technologies, enhancing disease prevention, and delivering high-quality vaccine solutions to improve publichealth and address global healthcare challenges. | $143.2M / Corporate Round / Jun 15, 2026 | |
|
Aomingxingcheng
|
Aomingxingcheng is a cutting-edge AI4S (AI for Science) technology company. | $14.6M / Series A / Apr 24, 2026 | |
TuringQ
|
Established in February 2021, TuringQ is committed to the research of quantum information. Through the R&D of lithium niobate on insulator (LNOI) photonic chips and femtosecond laser direct writing technology, the photon chips that enable large-scale photonic circuits integration can be prepared and an optical quantum system with a whole newlevel of scale and complexity can be built. At present, TuringQ has achieved leading advantages in photonic quantum chips, scientific research-grade photonic quantum computers, photonic quantum measurement and control systems, photonic quantum EDA software, and photonic quantum cloud platforms. | Series B / Jan 08, 2026 | |
|
Hengtai Bio
|
Hengtai Bio is a biotechnology company focused on pharmaceutical manufacturing, specializing in the research, development, and large-scale production of high-quality pharmaceutical products. | Angel / Aug 07, 2025 | |
Salus BioMed
|
Salus BioMed is an innovative biomedical company that specializes in developing genetic sequencing technology and spatial omics products. | Series A / May 14, 2025 | |
Conjustar
|
Conjustar, a protein-conjugated medicine developer that has rapidly built a robust R&D pipeline through a combination of introduction and independent research and development. it delivers more effective and safer new cancer therapy options to the majority of cancer patients. | $13.6M / Seed / Jan 16, 2025 | |
Fosun Kite Biotechnology
|
Fosun Kite Biotechnology develops immune cell therapy products. Fosun Kite Biotechnology is a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, and U.S. Kite Pharma. | $1.4M / Corporate Round / Sep 16, 2024 | |
Bianjie.AI
|
Bianjie.AI specializes in research on blockchain product technology, application platform development, and solution consulting. | Series A / Sep 14, 2023 | |
Scolioscan
|
Scolioscan focuses on medical imaging technology research & development, self-service production and technology distribution and promotion. | $5.1M / Seed / May 18, 2023 | |
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Fosun Pharma invest in?
Fosun Pharma invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Funding Round stage. Most of the 44 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fosun Pharma's check size?
Fosun Pharma typically joins rounds of $5.1M–$31M at Seed and $1.4M–$17M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fosun Pharma participates in.
How do I contact Fosun Pharma?
Public channels for Fosun Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fosun Pharma?
The team at Fosun Pharma includes Cui Zhiping (Vice President and General Manager of VC Investment Department), Hongfei Jia (SVP, Joint Chief Investment Officer and General Manager of International Operations Department) and Wai Danny (Independent Non-Executive Director), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
